Analysis of the Entire Ryanodine Receptor type 1 and Alpha 1 Subunit of the Dihydropyridine Receptor (CACNA1S) Coding Regions for Variants Associated with Malignant Hyperthermia in Australian Families
Free accessResearch articleFirst published online March, 2015
Analysis of the Entire Ryanodine Receptor type 1 and Alpha 1 Subunit of the Dihydropyridine Receptor (CACNA1S) Coding Regions for Variants Associated with Malignant Hyperthermia in Australian Families
Defects in the genes coding for the skeletal muscle ryanodine receptor (RYR1) and alpha 1 subunit of the dihydropyridine receptor (CACNA1S) have been identified as causative for malignant hyperthermia (MH). Sixty-two MH susceptible individuals presenting to the same diagnostic centre had copy deoxyribonucleic acid, derived from muscle ribonucleic acid, sequenced to identify variants with the potential to be responsible for the MH phenotype in both RYR1 and CACNA1S. These genetic findings were combined with clinical episode details and in vitro contracture test results to improve our understanding of the Australian MH cohort. Twelve novel variants were identified in RYR1 and six in CACNA1S. Known RYR1 causative mutations were identified in six persons and novel variants in RYR1 and CACNA1S in a further 17 persons. Trends indicated higher mutation identification in those with more definitive clinical episodes and stronger in vitro contracture test responses.
LarachM.G., BrandomB.W., AllenG.C., GronertG.A., LehmanM.S.Cardiac Arrests and Deaths Associated with Malignant Hyperthermia in North America from 1987 to 2006.Anesthesiology2008; 108: 603–611.
3.
A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility.The European Malignant Hyperpyrexia Group.Br J Anaesth1984; 56: 1267–1269.
4.
OrdingH., BrancadoroV., CozzolinoS., EllisF.R., GlauberV., GonanoE.F.In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European Malignant Hyperthermia Group.Acta Anaesthesiol Scand1997; 41: 955–966.
5.
LarachM.G.Standardization of the caffeine halothane muscle contracture test. North American Malignant Hyperthermia Group.Anesth Analg1989; 69: 511–515.
6.
GillardE.F., OtsuK., FujiiJ., KhannaV.K., de LeonS., DerdemeziJ.A substitution of cysteine for arginine 614 in the ryanodine receptor is potentially causative of human malignant hyperther-mia.Genomics1991; 11: 751–755.
7.
RobinsonR., CarpenterD., ShawM-A, HalsallJ., HopkinsP.Mutations in RYR1 in malignant hyperthermia and central core disease.Human Mutation2006; 27: 977–989.
8.
CarpenterD., RingroseC., LeoV., MorrisA., RobinsonR.L., HalsallP.J.The role of CACNA1S in predisposition to malignant hyper-thermia.BMC Med Genet2009; 10: 104.
9.
LokeJ., MacLennanD.H.Malignant hyperthermia and central core disease: disorders of Ca2+ release channels.Am J Med1998; 104: 470–486.
10.
ProtasiF., PaoliniC., DaineseM.Calsequestrin-1: a new candidate gene for malignant hyperthermia and exertional/environmental heat stroke.J Physiol2009; 587: 3095–100.
11.
GilliesR., BjorkstenA., DavisM., Du SartD.Identification of genetic mutations in Australian malignant hyperthermia families using sequencing of RYR1 hotspots.Anaesth Intensive Care2008; 36: 391–403.
12.
SambuughinN., HolleyH., MuldoonS., BrandomB.W., de BantelA.M., TobinJ.R.Screening of the entire ryanodine receptor type 1 coding region for sequence variants associated with malignant hyperthermia susceptibility in the North American population.Anesthesiology2005; 102: 515–521.
13.
CarpenterD., RobinsonR.L., QuinnellR.J., RingroseC., HoggM., CassonF.Genetic variation in RYR1 and malignant hyper-thermia phenotypes.Br J Anaesth2009; 103: 538–548.
14.
KlinglerW., HeiderichS., GirardT., GravinoE., HeffronJ.J., JohannsenS.Functional and genetic characterization of clinical malignant hyperthermia crises: a multi-centre study.Orphanet J Rare Dis2014; 9: 8.
15.
HopkinsPMRH, SnoeckM.M., GirardT., GlahnK.P.E., EllisF.R., MüllerC.R.The European Malignant Hyperthermia Group guidelines for the investigation of malignant hyperthermia susceptibility.Br J Anaesth2014; In Press:.
AdzhubeiI.A., SchmidtS., PeshkinL., RamenskyV.E., GerasimovaA., BorkP.A method and server for predicting damaging mis-sense mutations.Nature Methods2010; 7: 248–249.
20.
DavydovE.V., GoodeD.L., SirotaM., CooperG.M., SidowA., BatzoglouS.Identifying a high fraction of the human genome to be under selective constraint using GERP++.PLoS Comput Biol2010; 6: e1001025.
21.
SiepelA., BejeranoG., PedersenJ.S., HinrichsA.S., HouM., RosenbloomK.Evolutionarily conserved elements in vertebrate, insect, worm, and yeast genomes.Genome Research2005; 15: 1034–1050.
MonnierN., Krivosic-HorberR., PayenJ.F., Kozak-RibbensG., NivocheY., AdnetP., ReyfordH.Presence of two different genetic traits in malignant hyperthermia families: implication for genetic analysis, diagnosis, and incidence of malignant hyper-thermia susceptibility.Anesthesiology2002; 97: 1067–1074.
24.
PironeA., SchredelsekerJ., TulucP., GravinoE., FortunatoG., FlucherB.E.Identification and functional characterization of malignant hyperthermia mutation T1354S in the outer pore of the Cavalpha1S-subunit.Am J Physiol Cell Physiol2010; 299: C1345–1354.
25.
KimJ.H., JarvikG.P., BrowningB.L., RajagopalanR., GordonA.S., RiederM.J.Exome sequencing reveals novel rare variants in the ryanodine receptor and calcium channel genes in malignant hyperthermia families.Anesthesiology2013; 119: 1054–1065.
26.
SatoK., PollockN., StowellK.Functional studies of RYR1 mutations in the skeletal muscle ryanodine receptor using human RYR1 complementary DNA.Anesthesiology2010; 112: 1350–1354.
27.
SatoK., RoeslC., PollockN., StowellK.M.Skeletal Muscle Ryanodine Receptor Mutations Associated with Malignant Hyperthermia Showed Enhanced Intensity and Sensitivity to Triggering Drugs when Expressed in Human Embryonic Kidney Cells.Anesthesiology2013; 119: 111–118.
28.
VukcevicM., BromanM., IslanderG., BodelssonM., Ranklev-TwetmanE., MüllerC.R.Functional properties of RYR1 mutations identified in Swedish patients with malignant hyperthermia and central core disease.Anesth Analgesia2010; 111: 185–190.
29.
YangT., TaT.A., PessahI.N., AllenP.D.Functional defects in six ryanodine receptor isoform-1 (RyR1) mutations associated with malignant hyperthermia and their impact on skeletal excitation-contraction coupling.The Journal Of Biological Chemistry2003; 278: 25722–25730.
30.
SchiemannA., DurholtE., PollockN., StowellK.Sequence capture and massively parallel sequencing to detect mutations associated with malignant hyperthermia.Br J Anaesth2013; 110: 122–127.
31.
RiosE., BrumG.Involvement of dihydropyridine receptors in excitation-contraction coupling in skeletal muscle.Nature1987; 325: 717–720.
32.
EltitJ.M., BannisterR.A., MouaO., AltamiranoF., HopkinsP.M., PessahI.N.Malignant hyperthermia susceptibility arising from altered resting coupling between the skeletal muscle L-type Ca2+ channel and the type 1 ryanodine receptor.Proceedings of the National Academy of Sciences of the United States of America2012; 109: 7923–7928.
33.
RobinsonR., CurranJ.L., EllisF.R., HalsallP.J., HallW.J., HopkinsP.M.Multiple interacting gene products may influence susceptibility to malignant hyperthermia.Annals of Human Genetics2000; 64: 307–320.
YamamotoL., MaiaL., AyubguerrieriD.G.P.13.10 High frequency of polymorphisms in the RYR1 gene in Brazilian patients with centronuclear myopathy.Neuromuscular Disorders2008; 18: 810.
36.
AllenG.C., LarachM.G., KunselmanA.R.The sensitivity and specificity of the caffeine-halothane contracture test: a report from the North American Malignant Hyperthermia Registry. The North American Malignant Hyperthermia Registry of MHAUS.Anesthesiology1998; 88: 579–588.
BrownR.L., PollockA.N., CouchmanK.G., HodgesM., HutchinsonD.O., WaakaR.A novel ryanodine receptor mutation and genotype-phenotype correlation in a large malignant hyper-thermia New Zealand Maori pedigree.Hum Mol Genet2000; 9: 1515–1524.
39.
GillardE., OtsuK., FujiiJ., DuffC., de LeonS., KhannaV.K.Polymorphisms and deduced amino acid substitutions in the coding sequence of the ryanodine receptor (RYR1) gene in individuals with malignant hyperthermia.Genomics1992; 13: 1247–1254.
40.
LevanoS., VukcevicM., SingerM., MatterA., TrevesS., UrwylerA.Increasing the number of diagnostic mutations in malignant hyperthermia.Hum Mutat2009; 30: 590–598.
41.
GuisS., Figarella-BrangerD., MonnierN., BendahanD., Kozak-RibbensG., MatteiJ.P.Multiminicore disease in a family susceptible to malignant hyperthermia: histology, in vitro con-tracture tests, and genetic characterization.Arch Neurol2004; 61: 106–113.
42.
DavisM., BrownR., DicksonA., HortonH., JamesD., LaingN.Malignant hyperthermia associated with exercise-induced rhabdomyolysis or congenital abnormalities and a novel RYR1 mutation in New Zealand and Australian pedigrees.Br J Anaesth2002; 88: 508–515.
